Allogene Therapeutics Inc ALLO
$2.09 $0.01 (0.48%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
ALLO Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Allogene Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Allogene Therapeutics Inc. Stock Analysis ALLO
United States Health Care Small Cap Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 150 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Allogene Therapeutics Inc (ALLO) Chart
Financial Metrics & Statements of Allogene Therapeutics Inc (ALLO)
FAQ's for Allogene Therapeutics Inc (ALLO)
- As of August 2026, Allogene Therapeutics Inc ALLO is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Allogene Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Allogene Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Allogene Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Allogene Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Allogene Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Allogene Therapeutics Inc (ALLO)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
